ArticleInvestigational new drugs2023

Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients.

Takehiro Tozuka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.